Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma

Myasthenic crisis and polymyositis induced by one dose of nivolumab

(2016) Toshihiro Kimura et al.   CANCER SCIENCE

Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients

(2015) P Y Yew et al.   BONE MARROW TRANSPLANTATION

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

(2015) Xiangjiao Meng et al.   CANCER TREATMENT REVIEWS

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

(2015) Jason J. Luke et al.   Oncotarget

Highly clonal regulatory T-cell population in follicular lymphoma – inverse correlation with the diversity of CD8+T cells

(2015) Xiao Liu et al.   OncoImmunology

Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing

(2015) Miran Jang et al.   OncoImmunology

PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients

(2014) X Wu et al.   BRITISH JOURNAL OF CANCER

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression

(2014) Selena Viganò et al.   PLoS Pathogens

Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS)

(2014) Hua Fang et al.   OncoImmunology

Immune Modulation in Cancer with Antibodies

(2013) David B. Page et al.   Annual Review of Medicine

Exploiting the curative potential of adoptive T-cell therapy for cancer

(2013) Christian S. Hinrichs et al.   IMMUNOLOGICAL REVIEWS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER